3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
121
Lymphoma, Mantle-Cell
68
Lymphoma, Large B-Cell, Diffuse
40
Lymphoma, Non-Hodgkin
31
Lymphoma, Follicular
30
Waldenstrom Macroglobulinemia
29
Lymphoma
29
Recurrence
22
Lymphoma, B-Cell
22
Lymphoma, B-Cell, Marginal Zone
19
Neoplasms
14
Leukemia
13
Leukemia, B-Cell
10
Burkitt Lymphoma
8
Leukemia, Lymphoid
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Hodgkin Disease
5
Leukemia, Prolymphocytic
4
Bronchiolitis Obliterans Syndrome
4
Multiple Myeloma
3
Lymphoproliferative Disorders
3
Lymphatic Diseases
3
Leukemia, Myeloid, Acute
3
Immunoproliferative Disorders
3
Immune System Diseases
3
Hematologic Neoplasms
3
Hematologic Diseases
3
Chromosome 17 deletion
3
Leukemia, Prolymphocytic, B-Cell
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Interventions
ibrutinib
1
Standard of Care
1
Nivolumab
1
Lenalidomide
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurologic Manifestations
×
ibrutinib
×
Lymphoid
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled